Vivoryon Therapeutics Reports Q1 2026 Loss, Highlights Kidney-Disease Data and Funding Needs
When the next wave of kidney‑disease treatments is on the horizon, Vivoryon Therapeutics’ Q1 results paint a clear picture of progress and the challenges that lie ahead.The Dutch‑liste...
Read story →